{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T03:05:15Z","timestamp":1771556715166,"version":"3.50.1"},"reference-count":23,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Glaucoma"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.ogla.2022.08.015","type":"journal-article","created":{"date-parts":[[2022,8,31]],"date-time":"2022-08-31T04:29:48Z","timestamp":1661920188000},"page":"198-205","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Phase \u2160\/\u2161, Double-Masked, Randomized, Vehicle-Controlled Study of H-1337 Ophthalmic Solution for Glaucoma and Ocular Hypertension"],"prefix":"10.1016","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7496-7287","authenticated-orcid":false,"given":"Paul J.","family":"Hartman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8126-853X","authenticated-orcid":false,"given":"David L.","family":"Cooke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry H.","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeanette","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kengo","family":"Sumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoko","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyoshi","family":"Hidaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9699-8543","authenticated-orcid":false,"given":"Gary D.","family":"Novack","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ogla.2022.08.015_bib1","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMra0804630","article-title":"Primary open-angle glaucoma","volume":"360","author":"Kwon","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ogla.2022.08.015_bib2","series-title":"Terminology and Guidelines for Glaucoma","year":"2014"},{"key":"10.1016\/j.ogla.2022.08.015_bib3","doi-asserted-by":"crossref","first-page":"P41","DOI":"10.1016\/j.ophtha.2015.10.053","article-title":"Primary open-angle glaucoma preferred practice pattern guidelines","volume":"123","author":"Prum","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ogla.2022.08.015_bib4","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/S0140-6736(18)32213-X","article-title":"Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomized controlled trial","volume":"393","author":"Gazzard","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ogla.2022.08.015_bib5","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/ceo.13989","article-title":"Medical therapy for glaucoma: a review","volume":"50","author":"Casson","year":"2022","journal-title":"Clin Exp Ophthalmol"},{"key":"10.1016\/j.ogla.2022.08.015_bib6","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ajo.2017.11.019","article-title":"Two phase 3 clinical trials comparing the safety and efficacy of netarsudil to timolol in patients with elevated intraocular pressure: Rho kinase elevated IOP treatment trial 1 and 2 (ROCKET-1 and ROCKET-2)","volume":"186","author":"Serle","year":"2018","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ogla.2022.08.015_bib7","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ajo.2019.01.003","article-title":"Long-term safety and ocular hypotensive efficacy evaluation of netarsudil ophthalmic solution","volume":"200","author":"Kahook","year":"2019","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ogla.2022.08.015_bib8","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1001\/jamaophthalmol.2015.0525","article-title":"Additive intraocular pressure-lowering effects of the Rho kinase inhibitor ripasudil (K-115) combined with timolol or latanoprost: a report of 2 randomized clinical trials","volume":"133","author":"Tanihara","year":"2015","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ogla.2022.08.015_bib9","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/0076-6879(91)01029-2","article-title":"Properties and use of H-series compounds as protein kinase inhibitors","volume":"201","author":"Hidaka","year":"1991","journal-title":"Methods Enzymol"},{"key":"10.1016\/j.ogla.2022.08.015_bib10","doi-asserted-by":"crossref","first-page":"5036","DOI":"10.1021\/bi00316a032","article-title":"Isoquinolinesulfonamides, novel and potent inhibitors of cyclic nucleotide-dependent protein kinase and protein kinase C","volume":"23","author":"Hidaka","year":"1984","journal-title":"Biochemistry"},{"key":"10.1016\/j.ogla.2022.08.015_bib11","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.bmcl.2013.12.085","article-title":"IOP-lowering effect of isoquinoline-5-sulfonamide compounds in ocular normotensive monkeys","volume":"24","author":"Sumi","year":"2014","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.ogla.2022.08.015_bib12","first-page":"1781","article-title":"Isoquinoline sulfonamides such as fasudil, H-1152, ripasudil, and H-1129 produce IOP-lowering and neuroprotective effects through Rho kinase inhibition","volume":"59","author":"Sumi","year":"2018","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ogla.2022.08.015_bib13","first-page":"5695","article-title":"Elucidation of molecular mechanism of H-1337, an anti-glaucoma agent","volume":"56","author":"Kasai","year":"2015","journal-title":"Invest Ophthal Vis Sci"},{"key":"10.1016\/j.ogla.2022.08.015_bib14","doi-asserted-by":"crossref","DOI":"10.1074\/mcp.M110.001172","article-title":"A QUICK screen for Lrrk2 interaction partners\u2014leucine-rich repeat kinase 2 is involved in actin cytoskeleton dynamics","volume":"10","author":"Meixner","year":"2011","journal-title":"Mol Cell Proteomics"},{"key":"10.1016\/j.ogla.2022.08.015_bib15","first-page":"5712","article-title":"A\u00a0novel isoquinoline sulfonamide protein kinase inhibitor (H-1337) produces long-lasting reduction of IOP","volume":"56","author":"Hidaka","year":"2015","journal-title":"Invest Ophthal Vis Sci"},{"key":"10.1016\/j.ogla.2022.08.015_bib16","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1001\/archopht.124.9.1230","article-title":"Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial","volume":"124","author":"Sherwood","year":"2006","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ogla.2022.08.015_bib17","first-page":"166","article-title":"Power estimates in designing glaucoma trials","volume":"11","author":"Novack","year":"1989","journal-title":"Glaucoma"},{"key":"10.1016\/j.ogla.2022.08.015_bib18","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1001\/jamaophthalmol.2013.323","article-title":"Phase 1 clinical trials of a selective Rho kinase inhibitor, K-115","volume":"131","author":"Tanihara","year":"2013","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ogla.2022.08.015_bib19","doi-asserted-by":"crossref","first-page":"e393","DOI":"10.1111\/aos.12641","article-title":"Efficacy and safety of SNJ-1656 in primary open-angle glaucoma or ocular hypertension","volume":"93","author":"Inoue","year":"2015","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.ogla.2022.08.015_bib20","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1089\/108076801750125612","article-title":"Intraocular pressure-lowering efficacy of latanoprost in patients with normal-tension glaucoma or primary open-angle glaucoma","volume":"17","author":"Tamada","year":"2001","journal-title":"J\u00a0Ocul Pharmacol Ther"},{"key":"10.1016\/j.ogla.2022.08.015_bib21","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/sj.eye.6701373","article-title":"A\u00a0three-year prospective, randomized and open comparison between latanoprost and timolol in Japanese normal-tension glaucoma patients","volume":"18","author":"Tomita","year":"2004","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.ogla.2022.08.015_bib22","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.ajo.2011.04.012","article-title":"Ocular hypotensive effect of the Rho kinase inhibitor AR-12286 in patients with glaucoma and ocular hypertension","volume":"152","author":"Williams","year":"2011","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ogla.2022.08.015_bib23","first-page":"754","article-title":"Evaluation of AR-13324, a novel dual mechanism agent, in lowering of IOP in glaucoma and ocular hypertension","volume":"54","author":"Weiss","year":"2013","journal-title":"Invest Ophthal Vis Sci"}],"container-title":["Ophthalmology Glaucoma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589419622001703?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589419622001703?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T18:53:09Z","timestamp":1762887189000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589419622001703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S2589419622001703"],"URL":"https:\/\/doi.org\/10.1016\/j.ogla.2022.08.015","relation":{},"ISSN":["2589-4196"],"issn-type":[{"value":"2589-4196","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase \u2160\/\u2161, Double-Masked, Randomized, Vehicle-Controlled Study of H-1337 Ophthalmic Solution for Glaucoma and Ocular Hypertension","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Glaucoma","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ogla.2022.08.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 by the American Academy of Ophthalmology","name":"copyright","label":"Copyright"}]}}